A study of the immune response to vaccination in MS patients treated with alemtuzumab.
Phase of Trial: Phase IV
Latest Information Update: 16 Nov 2011
At a glance
- Drugs DT-poliovirus vaccine; Hib-meningococcal vaccine group C conjugate; Pneumococcal vaccine
- Indications Diphtheria; Haemophilus infections; Pneumococcal infections; Poliomyelitis; Tetanus
- Focus Pharmacodynamics
- Acronyms CAM-VAC
- 16 Nov 2011 Planned end date changed from 23 Jun 2013 to 28 Jul 2011 as reported by European Clinical Trials Database.
- 16 Nov 2011 Status changed from recruiting to discontinued as reported by European Clinical Trials Database.
- 15 Jun 2011 New trial record